New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures
Journal of Medicine and Therapeutics · 2017
DOI: 10.15761/jmt.1000119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicine and Therapeutics, 2017. Verfasst von Jason M. Hafron und 13 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Over diagnosis and overtreatment of indolent prostate cancer (PC) is a serious health issue. There is an unmet clinical need for noninvasive, easy to administer, diagnostic assay to help assess whether a prostate biopsy is warranted.
Objective
The performance of a novel, serum-based multiplexed autoantibody assay was assessed on a new, more sensitive Magneto-sensing assay using eight (8) autoantibodies plus standard of care (SOC) (PSA and age) vs. SOC alone for discriminating prostate cancer risk on biopsy as well as detecting highgrade prostate cancer on biopsy (Gleason Score (GS) 7 or greater).
Methods
Using the magneto-sensing technology, the levels of eight (8) autoantibodies were determined among 250 men with PSA levels 2-20 ng/mL using retrospective serum samples from two academic and one community clinical sites. Eligible men were PC-free, >40 years old, undergoing prostate biopsy due to suspicious digital rectal examination finding and/or elevated PSA levels. We evaluated the predictive ability of the autoantibody assay plus SOC using the area under receiver operating characteristic curve (AUC) to predict PC vs. no cancer on biopsy and high-grade PC defined as GS7 or greater from GS6/no cancer on biopsy. Analyses were repeated restricting to those with PSA 2-10 ng/ml and stratifying by age (
Zitieren
APA
Hafron, J. M., Yu, H., Juang, A., Vuong, D., Kamer, S., Carbonell, L., Singh, S., Reinhard, R., Arthurs, J., Ohrnberger, J., Fish, A. L., Arbor, A., Kapphahn, K., & Rajan, R. (2017). New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures. Journal of Medicine and Therapeutics. https://doi.org/10.15761/jmt.1000119
Vancouver
Hafron JM, Yu H, Juang A, Vuong D, Kamer S, Carbonell L, et al. New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures. Journal of Medicine and Therapeutics. 2017. doi:10.15761/jmt.1000119
BibTeX
@article{Hafron2017,
author = {Hafron, Jason M. and Yu, Heng and Juang, Alice and Vuong, Doris and Kamer, Sandy and Carbonell, Luis and Singh, Sharat and Reinhard, Robert and Arthurs, Jim and Ohrnberger, Jeanne and Fish, Amanda L and Arbor, Ann and Kapphahn, Kristopher and Rajan, Ravi},
title = {New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures},
journal = {Journal of Medicine and Therapeutics},
year = {2017},
doi = {10.15761/jmt.1000119}
}
EUVIMED